Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Israel / NCT04305808
Active, not recruiting Observational

Characterization of Vaginal, Urinary and Fecal Microbiomes in Women With Recurrent Urinary Tract Infections

NCT04305808 · tracked via the Priya Life Science Israel tracker
Sponsor
Hadassah Medical Organization
Phase
Observational
Started
2021-08-01
Last updated
2026-10-29

Condition(s) studied

Urinary Tract InfectionsMenopause

Study summary

The objectives are to evaluate whether variations in vaginal and/or urinary and/or fecal microbiome predispose postmenopausal women to recurrent cystitis. This will be explored using comparison of microbiome profiles between those with recurrent UTI compared to age-matched women without recurrent UTI.

Eligibility

Sex
FEMALE
Min age
—
Max age
—
Healthy volunteers
Accepted
Patients' inclusion criteria: * Menopausal status * Two or more documented, culture-positive infections in the last six months or ≥3 infections in the last year Patients' exclusion criteria: * Neurogenic bladder condition * Known immunodeficiencies * Usage of antibiotics or probiotics within the previous month * Known renal calculi or anatomic malformations Control subjects- Inclusion criteria: * Menopausal status * Sterile urine cultures, normal urinalysis, and negative sexually-transmitted PCR urine assay Control subjects- Exclusion criteria: \- A prior history of UTIs or other urologic abnormalities.

Primary outcome measure(s)

  • Characterization of the microbiome using molecular methods. — 1 year
    Comparison of microbiome profiles between those with rUTI compared to healthy controls.

Trial sites (1)

FacilityCityRegionStatus
Hadassah Medical Center Jerusalem Israel

More Hadassah Medical Organization trials in Israel

Dipyridamole for Early-Onset Preeclampsia: A Pilot Study of Feasibility, Pharmacokinetics, and Biological Effects Starting soon
The Computerized Retraining and Functional Treatment - Group Intervention Recruiting
Testis Needle Aspiration of Sperm in Men With Azoospermia Recruiting
Vaginal Microbiome Transplantation for Recurrent Bacterial Vaginosis Active, not recruiting
Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04305808 on ClinicalTrials.gov ↗ ← All trials in Israel